These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 22292365)

  • 21. Establishment of safety evidence for Xingxue Shuxuening injection.
    Yang W; Zhang W; Xie Y; Han B
    J Tradit Chin Med; 2014 Oct; 34(5):604-8. PubMed ID: 25417413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toxicological risks of Chinese herbs.
    Shaw D
    Planta Med; 2010 Dec; 76(17):2012-8. PubMed ID: 21077025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System.
    Clark JA; Humphries JE; Crean S; Reynolds MW
    Pharmacoepidemiol Drug Saf; 2010 Feb; 19(2):107-14. PubMed ID: 20014051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postmarketing studies on safety of Dengfeng shenmai injection.
    Wang L; Zhang W; Xie Y; Bai Y; Wang M; Ai Q
    J Tradit Chin Med; 2013 Dec; 33(6):827-31. PubMed ID: 24660618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postmarketing evaluation on the safety and effectiveness of deng-zhanxixin injection made from Dengzhanxixin (Herba Erigerontis Breviscapi).
    Li Y; Lin G; Xie Y; Zhang W; Guo T
    J Tradit Chin Med; 2015 Feb; 35(1):99-103. PubMed ID: 25842735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and analysis of post-marketing research.
    Zhou XH; Yang W
    Chin J Integr Med; 2013 Jul; 19(7):488-93. PubMed ID: 23818199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Systematic review on the application and adverse reactions of shengmai injection].
    Li TQ; Liu XM; Feng M
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Nov; 29(11):965-9. PubMed ID: 20329602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Literature review of application of shenmai injection in special populations (children)].
    Zhang XL; Ma R; Xie YM; Li M; Rong P
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3195-9. PubMed ID: 24471351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparative study on four kinds of assessment methods of post-marketing safety of Danhong injection].
    Li X; Tang J; Meng F; Li C; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2786-8. PubMed ID: 22292365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety monitoring of new anti-malarials in immediate post-marketing phase.
    Edwards IR
    Med Trop (Mars); 1998; 58(3 Suppl):93-6. PubMed ID: 10212911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Literature review on premarketing and postmarketing evidence of xiyanping injection].
    Wang ZF; Chen X; Zhang W; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3637-40. PubMed ID: 25532411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Literature review of post-marketing clinical evaluation of Xiaoke pill].
    Liu H; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2851-4. PubMed ID: 22292383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 2.